These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15548704)

  • 1. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
    Merchant MS; Yang X; Melchionda F; Romero M; Klein R; Thiele CJ; Tsokos M; Kontny HU; Mackall CL
    Cancer Res; 2004 Nov; 64(22):8349-56. PubMed ID: 15548704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
    Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
    Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
    Wang Y; Mandal D; Wang S; Kleinerman ES; Pollock RE; Lev D; Hayes-Jordan A
    Cancer; 2010 Aug; 116(16):3892-902. PubMed ID: 20564078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells.
    Abadie A; Besançon F; Wietzerbin J
    Oncogene; 2004 Jun; 23(28):4911-20. PubMed ID: 15077162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
    Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L; Zhang X; Barrisford GW; Olumi AF
    Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of caspase-8 and DR5 in TRAIL-induced apoptosis of neuroblastoma cells].
    Tong HX; Zhang JH; Ma L; Lu CW; Zhang JH
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):327-30. PubMed ID: 16923369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines.
    Kumar A; Jasmin A; Eby MT; Chaudhary PM
    Oncogene; 2001 Feb; 20(8):1010-4. PubMed ID: 11314037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
    Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
    Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression.
    Wang SH; Mezosi E; Wolf JM; Cao Z; Utsugi S; Gauger PG; Doherty GM; Baker JR
    Oncogene; 2004 Jan; 23(4):928-35. PubMed ID: 14647456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.
    Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U
    Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.